View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2013	Nov. 01, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	PLX
Entity Registrant Name	PROTALIX BIOTHERAPEUTICS, INC.
Entity Central Index Key	0001006281
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		93,561,765

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
CURRENT ASSETS:
Cash and cash equivalents	$ 91,397	$ 52,035
Accounts receivable- Trade	2,053	1,410
Other assets	4,173	3,686
Inventories	7,577	4,039
Total current assets	105,200	61,170
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT	1,467	1,247
PROPERTY AND EQUIPMENT, NET	14,340	16,310
DEFERRED CHARGES	149
Total assets	121,156	78,727
Accounts payable and accruals:
Trade	3,313	5,267
Other	12,400	11,051
Deferred revenues	9,513	9,437
Total current liabilities	25,226	25,755
LONG TERM LIABILITIES:
Deferred revenues	43,419	48,888
Convertible notes	66,944
Liability in connection with collaboration operation		5,425
Liability for employee rights upon retirement	2,273	2,016
Total long term liabilities	112,636	56,329
Total liabilities	137,862	82,084
COMMITMENTS
CAPITAL DEFICIENCY	(16,706)	(3,357)
Total liabilities net of capital deficiency	$ 121,156	$ 78,727

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
REVENUES	$ 2,284	$ 3,724	$ 8,116	$ 33,698
COMPANY'S SHARE IN COLLABORATION AGREEMENT	1,075	1,666	2,275	678
COST OF REVENUES	(1,587)	(2,367)	(3,876)	(6,966)
GROSS PROFIT	1,772	3,023	6,515	27,410
RESEARCH AND DEVELOPMENT EXPENSES	(7,723)	(8,326)	(23,467)	(27,717)
Less - grants and reimbursements	2,086	1,963	6,049	5,655
RESEARCH AND DEVELOPMENT EXPENSES, NET	(5,637)	(6,363)	(17,418)	(22,062)
GENERAL AND ADMINISTRATIVE EXPENSES	(1,780)	(2,220)	(6,065)	(7,353)
OPERATING LOSS	(5,645)	(5,560)	(16,968)	(2,005)
FINANCIAL INCOME (EXPENSES) - NET	(102)	81	63	264
NET LOSS FOR THE PERIOD	$ (5,747)	$ (5,479)	$ (16,905)	$ (1,741)
LOSS PER SHARE OF COMMON STOCK:
BASIC AND DILUTED	$ 0.06	$ 0.06	$ 0.18	$ 0.02
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:
BASIC AND DILUTED	92,433,502	91,929,445	92,307,170	90,491,421

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	$ 609	$ 1,247	$ 2,198	$ 3,690
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation	345	840	1,255	2,155
Cost of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation		$ 220		$ 220

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2011	$ (26,077)	$ 86	$ 145,814	$ (171,977)
Beginning Balance (in shares) at Dec. 31, 2011		85,630,157
Common stock issued for cash (net of issuance costs)	25,388	$ 5	25,383
Common stock issued for cash (net of issuance costs) (in shares)		5,175,000
Share-based compensation related to stock options	4,217		4,217
Share-based compensation related to restricted stock award, net of forfeitures	1,848	$ 1	1,847
Share-based compensation related to restricted stock award, net of forfeitures (in shares)		1,500,000
Exercise of options granted to employees	1,137	$ 1	1,136
Exercise of options granted to employees (in shares)		1,156,184
Net loss for the period	(1,741)			(1,741)
Ending Balance at Sep. 30, 2012	4,772	$ 93	178,397	(173,718)
Ending Balance (in shares) at Sep. 30, 2012		93,461,341
Beginning Balance at Dec. 31, 2012	(3,357)	$ 93	180,145	(183,595)
Beginning Balance (in shares) at Dec. 31, 2012		93,489,809
Share-based compensation related to stock options	895		895
Share-based compensation related to restricted stock award, net of forfeitures	2,558		2,558
Share-based compensation related to restricted stock award, net of forfeitures (in shares)		(1,667)
Exercise of options granted to employees	103	$ 1	102
Exercise of options granted to employees (in shares)		64,768
Net loss for the period	(16,905)			(16,905)
Ending Balance at Sep. 30, 2013	$ (16,706)	$ 94	$ 183,700	$ (200,500)
Ending Balance (in shares) at Sep. 30, 2013		93,552,910

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDER'S EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2013
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]
Common stock issued for cash, issuance costs	$ 1,780
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, Authorized	150,000,000	150,000,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,905)	$ (1,741)
Adjustments required to reconcile net loss to net cash used in operating activities:
Share based compensation	3,453	6,065
Depreciation and write down of fixed assets	2,689	2,772
Financial expenses (income), net (mainly exchange differences)	(140)	14
Changes in accrued liability for employee rights upon retirement	145	218
Gain on amounts funded in respect of employee rights upon retirement	(26)	(24)
Amortization of debt issuance costs and debt discount	15
Changes in operating assets and liabilities:
Decrease in deferred revenues (including non-current portion)	(5,393)	(4,981)
Increase in accounts receivable and other assets	(798)	(2,099)
Increase in inventories	(3,538)	(1,779)
Increase (decrease) in accounts payable and accruals (including long term )	(5,413)	369
Net cash used in operating activities	(25,911)	(1,186)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,668)	(1,817)
Amounts funded in respect of employee rights upon retirement, net	(121)	(93)
Investment in restricted deposit	(42)
Net cash used in investing activities	(1,831)	(1,910)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of convertible notes	66,930
Issuance of shares, net of issuance cost		25,328
Exercise of options	30	1,096
Net cash provided by financing activities	66,960	26,424
EFFECT OF EXCHANGE RATE CHANGES ON CASH	144	(113)
NET INCREASE IN CASH AND CASH EQUIVALENTS	39,362	23,215
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	52,035	27,001
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD	91,397	50,216
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:
Purchase of property and equipment	187	821
Issuance cost related to convertible note offering not yet paid	150
Exercise of options granted to employees	$ 73	$ 72

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2013

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

General

Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company's proprietary ProCellEx^® protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company's two subsidiaries are referred to collectively herein as the "Subsidiaries."

On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company's first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.

Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO™ by Pfizer Inc. ("Pfizer"), the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the "Pfizer Agreement"). The Company, through Protalix Ltd., markets ELELYSO in Israel.

Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel, and, subject to the effectiveness of the Brazil Agreement (as defined below), in Brazil. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA's approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, and, subject to the effectiveness of the Brazil Agreement, in Brazil, where the Company retained or will retain exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.

On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Fundação Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO^TM. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil Agreement becomes effective upon its approval by the Brazilian National Institute of Industrial Property, which is expected to occur very shortly.

To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.'s behalf in connection with the supply of taliglucerase alfa to Fiocruz.

Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.

In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.

Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil and Israel. In addition, patients are being treated globally through the Company's clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.

An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.

In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.

In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.

Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.

Net loss per share

Basic and diluted loss per share are calculated by dividing the net loss by the weighted average number of shares of the Company's common stock, par value $0.001 (the "Common Stock"), outstanding for each period.

Diluted loss per share does not include options, restricted shares and shares issuable upon conversion of the convertible notes issued in September 2013 (see Note 3) in the amount of 7,169,035 and 7,879,601 shares of Common Stock for the nine months ended September 30, 2012 and 2013, respectively, and 7,508,240 and 8,817,090 shares of Common Stock for the three months ended September 30, 2012 and 2013, respectively, because the effect would be anti-dilutive.

Convertible notes

The convertible notes are accounted for using the guidance provided set forth in FASB Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. The Company accounts for the convertible notes as a liability, on an aggregated basis, in their entirely.

INVENTORIES

9 Months Ended

Sep. 30, 2013

INVENTORIES [Abstract]

INVENTORIES

NOTE 2 - INVENTORIES

Inventory at September 30, 2013 and December 31, 2012 consisted of the following:

	September 30,		December 31,
	2013		2012
	(U.S. dollars in thousands)
Raw materials	$	2,574	$	2,118
Work in progress		140		192
Finished goods		4,863		1,729
Total inventory	$	7,577	$	4,039

Prior to the FDA's approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.

CONVERTIBLE NOTE

9 Months Ended

Sep. 30, 2013

CONVERTIBLE NOTE [Abstract]

CONVERTIBLE NOTE

NOTE 3 - CONVERTIBLE NOTE

On September 18, 2013, the Company completed a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018 (the "Notes"), including $9.0 million aggregate principal amount of Notes related to the initial purchaser's over-allotment option, which was exercised in full. In connection with the completion of the offering, the Company entered into an indenture (the "Indenture") with The Bank of New York Mellon Trust Company, N.A., as trustee, governing the Notes. The Notes accrue interest at a rate of 4.50% per year, payable semiannually in arrears on March 15 and September 15 of each year, beginning on March 15, 2014. The Notes mature on September 15, 2018.

The net proceeds from the offering, including net proceeds from the exercise in full by the initial purchaser of its option to purchase an additional $9.0 million in aggregate principal amount of the Notes, were $66.8 million, after deducting the initial purchaser's discount and commission and the estimated offering expenses payable by the Company.

Holders may convert their Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018. The initial conversion rate for the Notes is 173.6593 shares of the Common Stock for each $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.76 per share of the Common Stock. Upon conversion, the Company will deliver a number of shares of Common Stock, per $1,000 principal amount of Notes, equal to the conversion rate. The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.

Prior to September 19, 2016, the Company may not redeem the Notes, and no sinking fund is provided for the Notes. On or after September 19, 2016, the Company may redeem for cash all or part of the Notes (except for the notes that the Company is then required to repurchase in connection with a fundamental change, as defined below) if the last reported sale price of the Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading-day period ending on the trading day immediately preceding the date on which the Company provides the notice of redemption. The redemption price will equal the sum of (i) 100% of the principal amount of the Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date, plus (iii) the sum of the present values of each of the remaining scheduled payments of interest that would have been made on the Notes being redeemed had such Notes remained outstanding from the redemption date to the maturity date.

The following table sets forth total interest expense recognized related to the Notes (in thousands):

	Nine Months Ended				Three Months Ended
	September 30, 2013		September 30, 2012		September 30, 2013		September 30, 2012
Contractual interest expense	$	104		-	$	104		-
Amortization of debt issuance costs	$	15		-	$	15		-
Total	$	119		-	$	119		-

STOCK TRANSACTIONS	9 Months Ended
STOCK TRANSACTIONS	Sep. 30, 2013
STOCK TRANSACTIONS [Abstract]
STOCK TRANSACTIONS	NOTE 4 - STOCK TRANSACTIONS During the nine months ended September 30, 2013, the Company issued a total of approximately 64,768 shares of Common Stock in connection with the exercise of a total of approximately 64,768 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $103,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

FAIR VALUE MEASUREMENT	9 Months Ended
FAIR VALUE MEASUREMENT	Sep. 30, 2013
FAIR VALUE MEASUREMENT [Abstract]
FAIR VALUE MEASUREMENT	NOTE 5 - FAIR VALUE MEASUREMENT The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes as of September 30, 2013 is $71,760,000. The fair value was estimated based on quoted market prices.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

SIGNIFICANT ACCOUNTING POLICIES (Policy)

9 Months Ended

Sep. 30, 2013

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

General

General

In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.

Basis of Presentation

Basis of Presentation

Net loss per share

Net loss per share

Convertible notes

Convertible notes

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2013

INVENTORIES [Abstract]

Inventory

Inventory at September 30, 2013 and December 31, 2012 consisted of the following:

	September 30,		December 31,
	2013		2012
	(U.S. dollars in thousands)
Raw materials	$	2,574	$	2,118
Work in progress		140		192
Finished goods		4,863		1,729
Total inventory	$	7,577	$	4,039

CONVERTIBLE NOTE (Tables)

9 Months Ended

Sep. 30, 2013

CONVERTIBLE NOTE [Abstract]

Schedule of Interest Expense Recognized

The following table sets forth total interest expense recognized related to the Notes (in thousands):

	Nine Months Ended				Three Months Ended
	September 30, 2013		September 30, 2012		September 30, 2013		September 30, 2012
Contractual interest expense	$	104		-	$	104		-
Amortization of debt issuance costs	$	15		-	$	15		-
Total	$	119		-	$	119		-

SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 18, 2013 USD ($)	Sep. 30, 2009 USD ($)	Sep. 30, 2013 $ / shares shares	Sep. 30, 2012 $ / shares shares	Jun. 30, 2012 USD ($)	Sep. 30, 2013 $ / shares shares	Sep. 30, 2012 $ / shares shares
Significant Accounting Policies [Line Items]
Number of Subsidiaries						2
Pfizer Agreement, upfront payment received		$ 60,000
Common stock, par value per share \| $ / shares			$ 0.001	$ 0.001		$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive \| shares			8,817,090	7,508,240		7,879,601	7,169,035
Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage			40.00%			40.00%
Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage			60.00%			60.00%
Protalix Ltd. [Member]
Significant Accounting Policies [Line Items]
Supply commitment for entitled rights to be received	$ 280,000
License and supply agreement potential future payment	12,500
Supply commitment per year	$ 40,000
Upon Filing of Pediatric Investigation Plan to EMA [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received		$ 5,000
Upon FDA Approval [Member]
Significant Accounting Policies [Line Items]
Milestone payment triggered					$ 25,000

INVENTORIES (Schedule of Inventory Components) (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Dec. 31, 2012
INVENTORIES [Abstract]
Raw materials	$ 2,574	$ 2,118
Work in process	140	192
Finished goods	4,863	1,729
Total inventory	$ 7,577	$ 4,039

CONVERTIBLE NOTE (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Sep. 18, 2013	Sep. 30, 2013	Sep. 30, 2012
CONVERTIBLE NOTE [Abstract]
Principal amount	$ 69,000
Debt additional principal amount	$ 9,000
Interest rate	4.50%
Base value for conversion rate	$ 1
Number of shares for basis conversion	173.6593
Conversion price per share	$ 5.76
Net proceeds from issuance of convertible notes	$ 66,800	$ 66,930
Maturity	Sep. 15, 2018

CONVERTIBLE NOTE (Schedule of Interest Expense Recognized) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
CONVERTIBLE NOTE [Abstract]
Contractual interest expense	$ 104		$ 104
Amortization of debt issuance costs	15		15
Total	$ 119		$ 119

STOCK TRANSACTIONS (Details) - USD ($) $ in Thousands	9 Months Ended
STOCK TRANSACTIONS (Details) - USD ($) $ in Thousands	Sep. 30, 2013	Sep. 30, 2012
Class of Stock [Line Items]
Cash proceeds from exercise of options	$ 30	$ 1,096
Certain Employee [Member]
Class of Stock [Line Items]
Exercise of options granted to employees (in shares)	64,768
Cash proceeds from exercise of options	$ 103
Common stock issued in connection with exercise of options	64,768

FAIR VALUE MEASUREMENT (Details) $ in Thousands	Sep. 30, 2013 USD ($)
FAIR VALUE MEASUREMENT [Abstract]
Fair value convertible notes	$ 71,760